Allergovac Depot

Phase 1Biologic

RRoxall Medicina España S.A

Allergovac Depot is one of 29 biologic programs targeting Conjunctivitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConjunctivitisActive, not recruiting

ConjunctivitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Conjunctivitis

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

2 2

Neoral

Novartis

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Tobrex

VViatris Specialty LLC

Approved

1 5

Lotemax

BBausch & Lomb Incorporated

Approved

1 6

Levaquin

WWim Janssens

Approved

—7

Prograf

VVeloxis Pharmaceuticals

Approved

—8

Decadron

AAspen Global Incorporated

Phase 3

1 9

Claritin

PPerrigo Company

Phase 3

1 10

Cytovene

EExela Pharma Sciences, LLC.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Conjunctivitis4 trials

A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense

Completed·RRoxall Medicina España S.A·Phase 1·NCT02849249·52 enrolled

A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

Completed·RRoxall Medicina España S.A·Phase 1·NCT02477917·51 enrolled

Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites

Completed·RRoxall Medicina España S.A·Phase 1·NCT02881879·43 enrolled

Show 1 more trial

Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice

Completed·RRoxall Medicina España S.A··NCT02844842·152 enrolled

Immunotherapy2 trials

Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense

Completed·RRoxall Medicina España S.A·Phase 2·NCT01567306·151 enrolled

Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract

Completed·RRoxall Medicina España S.A·Phase 2·NCT01564017·150 enrolled

Clinical Trial1 trial

A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea

Completed·RRoxall Medicina España S.A·Phase 1·NCT02849210·47 enrolled

Treatment1 trial

Study to Evaluate the Safety of Treatment With A"LLERGOVAC® HIMENÓPTEROS" in Patients Sensitized to This Venom

Unknown status·RRoxall Medicina España S.A··NCT04112797·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Allergovac Depot. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergovac Depot compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergovac Depot. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roxall Medicina España S.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRoxall Medicina España S.A

Allergovac Depot

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Conjunctivitis4 trials

Immunotherapy2 trials

Clinical Trial1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News